# Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser

> **NCT01578421** · NA · COMPLETED · sponsor: **Kantonsspital Aarau** · enrollment: 31 (actual)

## Conditions studied

- Renal Failure Chronic Requiring Hemodialysis

## Interventions

- **DEVICE:** 4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)

## Key facts

- **NCT ID:** NCT01578421
- **Lead sponsor:** Kantonsspital Aarau
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578421, "Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01578421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*